The global pharmaceutical giant, GSK, plans to manufacture ten thousand doses of its experimental Ebola vaccine following the commencement yesterday in the UK of human trials of the medicine.
As it were, the world is pinning its hopes on the vaccine to contain an unprecedented outbreak in parts of West Africa.
The aim is to have the 10,000 doses of the experimental vaccine ready so that if the ongoing human trials are successful, stocks can be made available immediately to the World Health Organisation (WHO) to fortify health workers who are high risk of being infected.
Britain’s trial of an experimental vaccine against Ebola began in Oxford yesterday with the first healthy volunteer receiving the vaccine.
Ruth Atkins, 48, was injected with the candidate Ebola vaccine on Wednesday after a clinical assessment. She was the first of 60 volunteers to participate in the trial.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.